AbCellera Biologics Statistics
Share Statistics
AbCellera Biologics has 295.37M shares outstanding. The number of shares has increased by 0.88% in one year.
| Shares Outstanding | 295.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 221.93M |
| Failed to Deliver (FTD) Shares | 22.11K |
| FTD / Avg. Volume | 0.84% |
Short Selling Information
The latest short interest is 15.89M, so 5.38% of the outstanding shares have been sold short.
| Short Interest | 15.89M |
| Short % of Shares Out | 5.38% |
| Short % of Float | 7.16% |
| Short Ratio (days to cover) | 6.42 |
Valuation Ratios
The PE ratio is -11.28 and the forward PE ratio is -4.48.
| PE Ratio | -11.28 |
| Forward PE | -4.48 |
| PS Ratio | 43.42 |
| Forward PS | 13.1 |
| PB Ratio | 1.43 |
| P/FCF Ratio | -13.6 |
| PEG Ratio | n/a |
Enterprise Valuation
AbCellera Biologics Inc. has an Enterprise Value (EV) of 1.73B.
| EV / Earnings | -11.81 |
| EV / Sales | 45.46 |
| EV / EBITDA | -9 |
| EV / EBIT | -7.29 |
| EV / FCF | -14.24 |
Financial Position
The company has a current ratio of 7.33, with a Debt / Equity ratio of 0.
| Current Ratio | 7.33 |
| Quick Ratio | 7.32 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.13% and return on capital (ROIC) is -16.23%.
| Return on Equity (ROE) | -0.13% |
| Return on Assets (ROA) | -0.1% |
| Return on Capital (ROIC) | -16.23% |
| Revenue Per Employee | 64.89K |
| Profits Per Employee | -249.83K |
| Employee Count | 586 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -27.63M |
| Effective Tax Rate | 0.16 |
Stock Price Statistics
The stock price has increased by -44.4% in the last 52 weeks. The beta is 0.35, so AbCellera Biologics 's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -44.4% |
| 50-Day Moving Average | 2.89 |
| 200-Day Moving Average | 3.11 |
| Relative Strength Index (RSI) | 43.71 |
| Average Volume (20 Days) | 2.62M |
Income Statement
In the last 12 months, AbCellera Biologics had revenue of 38.02M and earned -146.40M in profits. Earnings per share was -0.51.
| Revenue | 38.02M |
| Gross Profit | 38.02M |
| Operating Income | -237.21M |
| Net Income | -146.40M |
| EBITDA | -192.16M |
| EBIT | -237.21M |
| Earnings Per Share (EPS) | -0.51 |
Balance Sheet
The company has 133.32M in cash and 77.38M in debt, giving a net cash position of 55.94M.
| Cash & Cash Equivalents | 133.32M |
| Total Debt | 77.38M |
| Net Cash | 55.94M |
| Retained Earnings | 279.79M |
| Total Assets | 1.39B |
| Working Capital | 663.32M |
Cash Flow
In the last 12 months, operating cash flow was -43.88M and capital expenditures -77.51M, giving a free cash flow of -121.38M.
| Operating Cash Flow | -43.88M |
| Capital Expenditures | -77.51M |
| Free Cash Flow | -121.38M |
| FCF Per Share | -0.42 |
Margins
Gross margin is 100%, with operating and profit margins of -623.82% and -385%.
| Gross Margin | 100% |
| Operating Margin | -623.82% |
| Pretax Margin | -457.67% |
| Profit Margin | -385% |
| EBITDA Margin | -505.35% |
| EBIT Margin | -623.82% |
| FCF Margin | -319.22% |
Dividends & Yields
ABCL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -18.35% |
| FCF Yield | -14.78% |
Analyst Forecast
The average price target for ABCL is $8, which is 187.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 187.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 2 |